Data Supports Deramiocel’s Sustained Efficacy and Safety in Treating DMD--Improvements Seen in Multiple Cardiac and Skeletal Endpoints ...
Two posters presented at the CHEST 2024 annual meeting show that although inhaled treprostinil reduces hospitalizations in ...
LONDON and NEW YORK, Oct. 09, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicine company, today announced a poster presentation at ...
US campuses have played an actively complicit role in the CCP’s efforts to threaten international Chinese students into ...
The purpose of vaccinating children was originally to stop dangerous diseases that spread easily and quickly in a school room ...
Mumbai: Sun Pharmaceutical Industries Limited has announced that it will present abstracts across its dermatology portfolio ...
Zacks Small Cap Research on MSN11d
MNOV: MN-166 to be Evaluated in NIH-Sponsored Expanded Access Trial in ALS…MNOV READ THE FULL MNOV RESEARCH REPORT On September 30, 2024, MediciNova, Inc. (NASDAQ:MNOV) announced that MN-166 (ibudilast) will be evaluated in an Expanded Access Protocol (EAP) trial to evaluate ...
Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the EADV 2024 Congress ...
NDAQ:SRRK) Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 SAPPHIRE Study in Patients with Spinal Muscular ...
New Data to be Presented at IDWeek 2024 Reinforce Merck’s Broad and Diverse Vaccines and Infectious Disease Pipeline and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback